PTC Therapeutics, Inc. (PTCT)CEO sold ~$195K
Matthew B. Klein, CEO at PTC Therapeutics, Inc., sold ~$195K of PTC Therapeutics, Inc. shares.
- ~$195K
- Approx. value · 3,897 sh @ $50.10
- 280K
- Holds after · shares reported
- Traded
- Feb 19, 2025
- Filed
- Feb 21, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 31, 2024InsiderCEO sold ~$374K of PTCT shares in the open market
- Jan 7, 2025Insider · 6 peopleInsiders: 7 sales (~$395K)
- Jan 8, 2025Insider · 6 peopleInsiders: 7 sales (~$492K)
- Feb 19, 2025 · this disclosureInsiderCEO sold ~$195K of PTCT shares in the open market
What came next
- Feb 19, 2025Insider · 6 peopleInsiders: 7 sales (~$345K)
- Feb 20, 2025Insider · 7 peopleInsiders: 8 sales (~$586K)
- Mar 4, 2025InsiderDirector sold ~$63K of PTCT shares in the open market
- Mar 10, 2025Insider · 1 personInsiders: 4 sales (~$3.6M)
- Mar 11, 2025InsiderOfficer sold ~$300K of PTCT shares in the open market
- Mar 12, 2025Insider · 1 personInsiders: 2 sales (~$827K)
- Mar 13, 2025InsiderDirector sold ~$270K of PTCT shares in the open market
- Mar 14, 2025InsiderOfficer sold ~$246K of PTCT shares in the open market
- Mar 17, 2025Insider · 1 personInsiders: 4 sales (~$384K)
- Apr 2, 2025InsiderOfficer sold ~$42K of PTCT shares in the open market
- Apr 22, 2025InsiderCEO sold ~$137K of PTCT shares in the open market
- May 15, 2025InsiderOfficer sold ~$89K of PTCT shares in the open market
- May 16, 2025InsiderOfficer sold ~$41K of PTCT shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for PTC Therapeutics, Inc.
For PTC Therapeutics, Inc., OQRO holds 9 insider filings (SEC Form 4 or Form 144) and 7 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PTCT page.
Other recent filings by Matthew B. Klein, CHIEF EXECUTIVE OFFICER
- SEC Form 4 at PTC Therapeutics, Inc. (PTCT)Aug 6, 2025
- SEC Form 4 at PTC Therapeutics, Inc. (PTCT)Apr 24, 2025
- SEC Form 4 at PTC Therapeutics, Inc. (PTCT)Feb 21, 2025
- SEC Form 4 at PTC Therapeutics, Inc. (PTCT)Jan 10, 2025
- SEC Form 4 at PTC Therapeutics, Inc. (PTCT)Jan 10, 2025
The full history of Matthew B. Klein, CHIEF EXECUTIVE OFFICER is on the profile page.
How this filing works
Other disclosures at PTC Therapeutics, Inc.
- SEC Form 144Oct 9, 2026
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 9, 2026
- SEC Form 4Oct 7, 2026
- SEC Form 4Oct 7, 2026
- SEC Form 144Oct 7, 2026
Everything OQRO holds on this company is on its PTCT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
